John Edenfield
2016
ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS
2016 • Matteo Simonelli, Juan Manuel Sepúlveda-Sánchez, Alba A. Brandes, Jean‐Charles Soria, John Edenfield, Víctor Moreno, Jaime Gállego Pérez‐Larraya, C...
Open Author Page
Exploring foci of
2016-11-01
ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS
2016-11-01 • Matteo Simonelli, Juan Manuel Sepúlveda-Sánchez, Alba A. Brandes, Jean‐Charles Soria, John Edenfield, Víctor Moreno, Jaime Gállego Pérez‐Larraya, C...
CC-122 is a novel cereblon binding agent with multiple biological activities including potent immunomodulatory and anti-angiogenic effects. Following establishment of oral CC-122 3mg daily (QD) as the maximum tolerated dose (Blood 122:2905 2013), patients with CNS tumors were enrolled in an expansion cohort. As of Jan. 13, 2016, 47 patients with relapsed/refractory GBM and other brain tumors were enrolled: GBM (n=39), grade IV oligodendroglioma (n=1), grade III anaplastic oligoastrocytoma (1) grade II-III astrocyt…
Open Article Page
Delayed Sleep Phase Disorder
Split-Phase Electric Power
Phase Velocity
Sublimation (Phase Transition)
Phase Noise
Phase-Contrast Microscopy
Deposition (Phase Transition)
Fossil Fuel Phase-Out
Lunar Phase
Open Article Page